Clinical Trial Update: SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing SHR-A1811 with chemotherapy for platinum-resistant recurrent epithelial ovarian cancer is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• SHR-A1811

Snippet

Sponsor: Tongji Hospital | Conditions: Ovarian Cancer | Phase 3 | Status: NOT_YET_RECRUITING